Valsartan is still available, although its availability has been impacted by recalls due to the presence of nitrosamine impurities [1][2]. These impurities, specifically N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), were found in valsartan products manufactured by certain companies [3].
What happened with the valsartan recalls?
The recalls began in 2018 when regulatory agencies detected nitrosamine impurities in valsartan, a widely used medication for high blood pressure and heart failure [1][4]. The contamination was linked to a change in the manufacturing process by a supplier, Hetero Labs Limited, which produced the valsartan active pharmaceutical ingredient (API) [3][5]. These impurities are considered probable human carcinogens [3]. Consequently, numerous batches of valsartan and valsartan-containing combination drugs were recalled globally [1][6].
Which valsartan products were affected by recalls?
The recalls affected a significant number of valsartan products from various manufacturers. For instance, Teva Pharmaceuticals voluntarily recalled its valsartan tablets in the United States [7]. Other companies, such as Mylan and Aurobindo, also initiated recalls of valsartan products [8][9]. The U.S. Food and Drug Administration (FDA) has a dedicated page listing the valsartan recalls, including details on affected products and manufacturers [1].
How did the valsartan recalls impact drug availability?
The widespread recalls led to temporary shortages and reduced availability of valsartan in some markets [2][10]. This prompted regulatory bodies to allow alternative valsartan products that met impurity standards to enter the market and for some manufacturers to reformulate their products [11].
What are the safety concerns regarding valsartan impurities?
The primary safety concern associated with the valsartan recalls is the presence of nitrosamine impurities, NDMA and NDEA. These impurities are classified as probable human carcinogens, meaning they could increase the risk of cancer with long-term exposure [3]. Regulatory agencies have established acceptable intake limits for these impurities [12].
Can I still get valsartan if I need it?
Yes, valsartan is still available, but patients should be aware that not all products on the market may be affected by the recalls [1]. It is advisable to check with your pharmacist or doctor to ensure you are receiving valsartan that has been tested and found to be free of harmful nitrosamine impurities [3]. Regulatory agencies continue to monitor valsartan and other sartan medications for these impurities [13].
How are valsartan impurities being managed?
Manufacturers of valsartan and other sartan drugs have implemented enhanced testing protocols and revised manufacturing processes to prevent and detect nitrosamine impurities [11][14]. Regulatory agencies have also updated guidelines for manufacturers on controlling these impurities [15]. Ongoing surveillance and testing by health authorities aim to ensure the continued safety of these medications [13].